Form 8-K
8-K — Cue Biopharma, Inc.
Accession: 0001193125-26-330730
Filed: 2026-08-03
Period: 2026-07-27
CIK: 0001645460
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Documents
8-K — d134183d8k.htm (Primary)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d134183d8k.htm · Sequence: 1
8-K
NASDAQ false 0001645460 0001645460 2026-07-27 2026-07-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 27, 2026
Cue Biopharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38327
47-3324577
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
40 Guest Street
Boston, Massachusetts
02135
(Address of principal executive offices)
(Zip Code)
(617) 949-2680
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
CUE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(c) On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”). In connection with his appointment as Chief Financial Officer, Mr. Ahlers will serve as the Company’s principal financial officer.
Mr. Ahlers, age 62, most recently served as a consulting Chief Financial Officer and strategic advisor to emerging life sciences companies, providing finance leadership across public and private financings, initial public offering readiness, Securities and Exchange Act (“SEC”) reporting and compliance, Sarbanes-Oxley Act of 2002 compliance, investor relations, and the scaling of finance functions. His engagements included, among others, most recently Danforth Advisors, LLC from January 2022 to July 2026, Intensity Therapeutics, Inc. as CFO/Advisory to Public and Private from January 2022 to June 2023, RenovoRx, Inc. as Executive Vice President of Corporate Finance from June 2023 to May 2024 and as CFO, Secretary and Treasurer from July 2022 to February 2024, as well as services for Arsenal Biosciences, Inc., and RegCell Co., Ltd. Prior to these engagements, he served as a part-time independent consultant to emerging life sciences companies. He previously served for nearly two decades as Chief Financial Officer of Intarcia Therapeutics, a privately held biopharmaceutical company developing drugs, biologics, peptides, and drug-device combinations for serious and life-threatening diseases. During his tenure, he completed multiple preferred stock offerings with gross proceeds of more than $1 billion, more than $150 million in debt financings, and more than $600 million of structured financings. He also scaled the finance organization and systems to support corporate growth. Earlier, Mr. Ahlers held senior finance and administration roles at Titan Pharmaceuticals, where he managed numerous public securities offerings, and Ansan Pharmaceuticals, which became a Titan subsidiary. While there, he managed public securities offerings, served as principal financial officer for two initial public offerings, and led SEC reporting. He also held finance roles at Medco Behavioral Care and Spectrum Foods. He started his career at Deloitte & Touche. Mr. Ahlers holds a Bachelor of Science in Accounting from the University of San Francisco.
In connection with his employment, on July 28, 2026, Mr. Ahlers entered into an executive employment agreement with the Company (the “Ahlers Employment Agreement”). Pursuant to the Ahlers Employment Agreement, Mr. Ahlers will be paid an annualized base salary of $450,000. Following the end of each calendar year, Mr. Ahlers will be eligible to receive a discretionary annual incentive bonus with a target of up to 45% of his base salary based upon the assessment of key performance indicators for the Company by the Compensation Committee of the Board. In accordance with the Ahlers Employment Agreement, on the Effective Date, the Board granted to Mr. Ahlers, under the Company’s 2026 Inducement Stock Incentive Plan (the “Plan”), as an inducement material to Mr. Ahlers acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), (i) nonstatutory stock options (the “Initial Option”) to purchase 51,00 shares of the Company’s common stock and (ii) a restricted stock unit award for 25,500 shares of the Company’s common stock (the “Initial RSU” and together with the Initial Option, the “Initial Grants”). The Initial Option has an exercise price per share equal to $30.40, the closing price of the Company’s common stock on the Nasdaq Capital Market on the Effective Date. The Initial Grants will vest in equal quarterly installments over four years from the Effective Date, subject to Mr. Ahlers’ continued performance of services to the Company on each applicable vesting date.
Under the Ahlers Employment Agreement, Mr. Ahlers is entitled, subject to his execution and nonrevocation of a release of claims in the Company’s favor and his continued compliance with certain continuing obligations to the Company, in the event of a termination of his employment (i) by the Company other than for Cause or due to Mr. Ahlers’ death or Disability or (ii) by Mr. Ahlers for Good Reason (each as defined in the Ahlers Employment Agreement and each, a “Qualifying Termination”), to (i) a lump sum cash severance payment in an amount equal to the sum of (a) nine months of base salary plus (b) the target annual bonus amount for the year of termination, prorated based on the number of days that Mr. Ahlers is employed in such year through the date of termination, payable on the Company’s first payroll date that occurs more than 60 days after Mr. Ahlers termination, (ii) if Mr. Ahlers elects COBRA coverage for health and/or dental insurance in a timely manner, continued payment by the Company of the monthly premium payments for such health benefit coverage (consistent with what was in place at termination) until the earliest of (a) nine months following termination, (b) the date Mr. Ahlers obtains new employment that offers health and/or dental insurance that is reasonably comparable to that offered by the Company, and (c) the date COBRA continuation coverage would otherwise terminate in accordance with the provisions of COBRA, and (iii) all other payments, benefits or fringe benefits to which Mr. Ahlers is entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant.
If the Qualifying Termination occurs within the period commencing on the date that is 90 days prior to a “change in control” and ending on the date 24 months following a “change in control”, (i) with respect to issued and outstanding equity awards subject to time-vesting conditions, the vesting and exercisability of such awards shall accelerate in full, and (ii) with respect to issued and outstanding equity awards subject to performance-based vesting conditions, the service-based vesting conditions of such awards shall be deemed satisfied and the performance goals shall be deemed to be achieved at the greater of target or actual performance as of the “change in control”. With respect to equity awards described in (i) and (ii) in the prior sentence, such equity awards shall remain exercisable (if exercisable) until the earlier of one year from any termination/resignation or the latest date on which those equity awards expire or are eligible to be exercised under the applicable award agreements.
In connection with his appointment, Mr. Ahlers entered into the Company’s standard form indemnification agreement, a copy of which was filed as Exhibit 10.10 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 16, 2025. Pursuant to the terms of the indemnification agreement, the Company may be required to, among other things, indemnify Mr. Ahlers for certain expenses, including attorney’s fees, judgement, penalties, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as an officer of the Company.
There are no arrangements or understandings between Mr. Ahlers and any other persons pursuant to which he was selected as the Company’s Chief Financial Officer. Mr. Ahlers does not have any family relationships with any of the Company’s other directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. There are no relationships or transactions in which Mr. Ahlers has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.
The foregoing description of the Ahlers Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of such agreement, which will be filed with the SEC as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2026
Cue Biopharma, Inc.
By:
/s/ Shao-Lee Lin
Name:
Shao-Lee Lin
Title:
President and Chief Executive Officer
(Principal Executive Officer)
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 6
v3.26.1
Document and Entity Information
Jul. 27, 2026
Cover [Abstract]
Security Exchange Name
NASDAQ
Amendment Flag
false
Entity Central Index Key
0001645460
Document Type
8-K
Document Period End Date
Jul. 27, 2026
Entity Registrant Name
Cue Biopharma, Inc.
Entity Incorporation State Country Code
DE
Entity File Number
001-38327
Entity Tax Identification Number
47-3324577
Entity Address, Address Line One
40 Guest Street
Entity Address, City or Town
Boston
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02135
City Area Code
(617)
Local Phone Number
949-2680
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common Stock, par value $0.001 per share
Trading Symbol
CUE
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration